DONGKOOK PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17,700 KRW | +2.25% |
|
+4.12% | +9.53% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,83,159 | 12,85,488 | 9,58,073 | 7,29,658 | 7,10,431 | 7,78,133 | - | - |
| Enterprise Value (EV) 2 | 688.7 | 1,178 | 887.1 | 692.8 | 693 | 675.4 | 687.7 | 750.2 |
| P/E ratio | 14.2 x | 23.4 x | 19.4 x | 14 x | 15.3 x | 14.3 x | 10.9 x | 10.9 x |
| Yield | 0.9% | 0.62% | 0.83% | - | - | 1.02% | 1.02% | 1.02% |
| Capitalization / Revenue | 1.62 x | 2.3 x | 1.61 x | 1.1 x | 0.97 x | 0.96 x | 0.87 x | 0.79 x |
| EV / Revenue | 1.43 x | 2.11 x | 1.49 x | 1.05 x | 0.95 x | 0.83 x | 0.77 x | 0.76 x |
| EV / EBITDA | 8.38 x | 11.8 x | 11 x | 7.54 x | 7.88 x | 6.62 x | 5.34 x | 6 x |
| EV / FCF | 15.5 x | 60.4 x | -140 x | -111 x | 88.2 x | 12.5 x | 9.17 x | - |
| FCF Yield | 6.44% | 1.66% | -0.72% | -0.9% | 1.13% | 8.02% | 10.9% | - |
| Price to Book | 2.16 x | 3.18 x | 2.17 x | 1.45 x | 1.33 x | 1.35 x | 1.2 x | 1.13 x |
| Nbr of stocks (in thousands) | 43,948 | 43,948 | 43,948 | 43,955 | 43,962 | 43,962 | - | - |
| Reference price 3 | 17,820 | 29,250 | 21,800 | 16,600 | 16,160 | 17,700 | 17,700 | 17,700 |
| Announcement Date | 05/03/20 | 23/02/21 | 17/03/22 | 09/03/23 | 14/03/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 482.3 | 559.1 | 594.2 | 661.6 | 731 | 810.5 | 893.8 | 981.6 |
| EBITDA 1 | 82.2 | 99.84 | 80.58 | 91.84 | 87.97 | 102.1 | 128.7 | 125 |
| EBIT 1 | 68.58 | 83.61 | 63.22 | 72.65 | 66.87 | 78.2 | 107.7 | 100.1 |
| Operating Margin | 14.22% | 14.95% | 10.64% | 10.98% | 9.15% | 9.65% | 12.05% | 10.2% |
| Earnings before Tax (EBT) 1 | 75.63 | 81.29 | 69.75 | 68.63 | 60.84 | 74 | 96.1 | 97.1 |
| Net income 1 | 56.31 | 57.29 | 50.35 | 52.9 | 47.18 | 55.3 | 73.1 | 72.3 |
| Net margin | 11.68% | 10.25% | 8.47% | 7.99% | 6.45% | 6.82% | 8.18% | 7.37% |
| EPS 2 | 1,259 | 1,251 | 1,126 | 1,183 | 1,055 | 1,241 | 1,627 | 1,623 |
| Free Cash Flow 3 | 44,352 | 19,502 | -6,352 | -6,263 | 7,856 | 54,200 | 75,000 | - |
| FCF margin | 9,196.23% | 3,488.01% | -1,069% | -946.5% | 1,074.74% | 6,687.23% | 8,391.14% | - |
| FCF Conversion (EBITDA) | 53,955.51% | 19,531.84% | - | - | 8,930.51% | 53,085.21% | 58,275.06% | - |
| FCF Conversion (Net income) | 78,760.15% | 34,042.45% | - | - | 16,653.35% | 98,010.85% | 1,02,599.18% | - |
| Dividend per Share 2 | 160.0 | 180.0 | 180.0 | - | - | 180.0 | 180.0 | 180.0 |
| Announcement Date | 05/03/20 | 23/02/21 | 17/03/22 | 09/03/23 | 14/03/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 145 | 150.5 | 165.7 | 169.9 | 159.7 | 166.4 | 185.9 | 176.4 | 187.9 | 196.8 | 206.4 | 198.7 | 208.8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 11.53 | 16.29 | 23.41 | 19.96 | 11.86 | 17.42 | 12.91 | 14.19 | 20.46 | 21.01 | 18.6 | 18 | 21.3 |
| Operating Margin | 7.95% | 10.82% | 14.13% | 11.75% | 7.43% | 10.47% | 6.94% | 8.04% | 10.89% | 10.68% | 9.01% | 9.06% | 10.2% |
| Earnings before Tax (EBT) 1 | - | - | - | 19.96 | 14.3 | 12.79 | - | - | 13.54 | 25.13 | 22 | 21.5 | 29.6 |
| Net income 1 | 8.484 | 15.41 | - | 16.02 | 11.82 | 9.365 | - | - | 9.065 | 19.68 | 17.5 | 16.5 | 23 |
| Net margin | 5.85% | 10.24% | - | 9.43% | 7.4% | 5.63% | - | - | 4.83% | 10% | 8.48% | 8.3% | 11.02% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/11/21 | 17/03/22 | 16/05/22 | 16/08/22 | 14/11/22 | 09/03/23 | 11/08/23 | 14/11/23 | 14/03/24 | 16/05/24 | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 94.4 | 108 | 71 | 36.8 | 17.5 | 103 | 90.5 | 27.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | 44,352 | 19,502 | -6,352 | -6,263 | 7,856 | 54,200 | 75,000 | - |
| ROE (net income / shareholders' equity) | 17.5% | 14.4% | 11.6% | 11.1% | 9.01% | 9.7% | 11.5% | 10.6% |
| ROA (Net income/ Total Assets) | 11.5% | 9.26% | 7.12% | 6.97% | 5.87% | 6.4% | 7.75% | 7.3% |
| Assets 1 | 488.6 | 618.5 | 706.6 | 759.2 | 803.9 | 864.1 | 943.2 | 990.4 |
| Book Value Per Share 3 | 8,257 | 9,199 | 10,050 | 11,419 | 12,177 | 13,081 | 14,768 | 15,727 |
| Cash Flow per Share 3 | 1,581 | 1,322 | 999.0 | 915.0 | 934.0 | 1,705 | 1,893 | 2,095 |
| Capex 1 | 25.1 | 39.6 | 51 | 47.2 | 33.9 | 30.9 | 24.8 | 29.8 |
| Capex / Sales | 5.21% | 7.08% | 8.58% | 7.13% | 4.64% | 3.81% | 2.77% | 3.04% |
| Announcement Date | 05/03/20 | 23/02/21 | 17/03/22 | 09/03/23 | 14/03/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17,700
KRW
Average target price
24,000
KRW
Spread / Average Target
+35.59%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.53% | 575M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- A086450 Stock
- Financials DongKook Pharmaceutical Co., Ltd.
